Note:

Cardiac and Respiratory Foundation NZ is dedicated to improving heart and lung health outcomes. It brings together the Asthma and Respiratory Foundation NZ, Kia Manawanui Trust – The Heart of Aotearoa, Lung Foundation NZ, and the Bronchiectasis Foundation NZ.

Skip to content

Access to medicines and devices

Too many New Zealanders are waiting too long - or going without - treatments and diagnostic tools that are already proven to work.

TEER device

The problem

When a medicine or device is recommended by international cardiac and respiratory guidelines, the evidence is there - it works.

But in New Zealand, patients can still face long waits, or no pathway at all, to access those treatments.

Pharmac's assessment process was built for medicines. There is no equivalent fit-for-purpose pathway for medical devices, which means patients and clinicians are navigating a system that wasn't designed for what they need.

The result is that treatments proven to improve outcomes overseas are reaching New Zealand too slowly, or not at all.

The solution

The Cardiac and Respiratory Foundation NZ is calling on the Government to:

  • Create a fit-for-purpose Pharmac assessment pathway for medical devices
  • Fast-track medicines and devices already recommended in international cardiac and respiratory guidelines
  • Ensure New Zealand patients can access proven treatments without unnecessary delays

Kiwi families face ‘ticking time bomb’ without funded heart drugs

Heart clocking ticking - purchase in July

PCSK9 inhibitors could transform the lives of people with familial hypercholesterolaemia, but they're not funded in New Zealand, leaving thousands at risk of early heart attacks.